Tricol Biomedical Receives NIH Phase IIB Grant to Continue Development of its Hemostatic Device for the Prostate
Tricol Biomedical Receives NIH Phase IIB Grant to Continue Development of its Hemostatic Device for the Prostate
07 oct. 2021 11h00 HE | Tricol Biomedical
Portland, OR, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Tricol Biomedical, a privately held medical device company dedicated to saving lives through innovative hemostatic and wound care solutions, has...